Konruns released its performance for the first three quarters, with a net profit attributable to the parent company of 128 million yuan, a year-on-year increase of 13.19%

According to the Zhitong Finance APP, Konruns disclosed its third-quarter report for 2025. The company achieved revenue of 692 million yuan in the first three quarters, a year-on-year increase of 7.10%; net profit attributable to the parent company was 128 million yuan, a year-on-year increase of 13.19%; net profit excluding non-recurring gains and losses was 133 million yuan, a year-on-year increase of 25.90%; basic earnings per share were 0.81 yuan

Konruns: Plans to repurchase company shares for 50 million to 100 million yuan

Konruns announced that it plans to repurchase company shares for between 50 million and 100 million yuan, with a repurchase price not exceeding 82 yuan per share. All repurchased shares will be used for the employee stock ownership plan or equity incentives. The estimated number of repurchased shares is between 609,800 and 1,219,500, accounting for 0.38% to 0.77% of the company's total share capital. The funds for the repurchase will come from the company's own funds or self-raised funds, and the repurchase period is within 12 months after the board of directors' approval

A-share innovative drug concept stocks fluctuated lower, with BETTA PHARMACEUTICALS falling over 10%, Jincheng Pharm, Konruns, Baillie Tianheng, Olymvax Biopharmaceuticals, and CCHT all dropping more than 5%

Konruns: KC1036 combined with PD-1 antibody and platinum-based chemotherapy has been approved for clinical trials as a first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinoma

Konruns announced that it has received approval from the National Medical Products Administration to conduct clinical trials for KC1036 in combination with PD-1 antibodies and platinum-based chemotherapy as first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinoma. KC1036 is a Class 1 innovative drug independently developed by the company, which has anti-tumor activity and good safety. Clinical research has been conducted in multiple indications, with over 300 participants involved

Innovative drug concept stocks surged and then fell back, with Mengke Pharmaceutical dropping over 10%, BrightGene, Bio-S falling over 7%, and YKYY, Konruns, EASTON BIOPHARMACEUTICALS, Fushine among those with the largest declines